Prurigo nodularis (PN), one of the various subtypes of prurigo, is a chronic, bothersome-to-debilitating disease of the skin, usually seen as multiple, intensely pruritic, and excoriated nodules erupting on the surfaces of the extremities with intense itching or rubbing. PNs are cutaneous lesions often produced by repetitive scratching; hence the nickname “picker’s nodules”, which may occur as a sequel to chronic pruritus or neurotic excoriations.
As per DelveInsight’s analysis, it has been observed that most of the patients with Atopic PN account for 75% of the total diagnosed Prurigo Nodularis cases, followed by Nonatopic Prurigo Nodularis (25%) in the United States. In 2017, there were 116,653 Atopic PN and 38,884 Nonatopic PN patients.
DelveInsight's "Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Prurigo Nodularis Market, historical and forecasted epidemiology, the pipeline insight as well as the Prurigo Nodularis market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Prurigo Nodularis Market Growth Analysis
The Prurigo Nodularis (PN) market size is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period.
The Prurigo Nodularis market analysis section of the report helps to build a detailed comprehension of the historic, current, and forecasted Prurigo Nodularis market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
Prurigo Nodularis Epidemiology Forecast
The Prurigo Nodularis epidemiology section covers insights about historical and current Prurigo Nodularis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Prurigo Nodularis Pipeline Analysis
The Prurigo Nodularis Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Prurigo Nodularis market or expected to get launched in the market during the study period. The analysis covers the Prurigo Nodularis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the Prurigo Nodularis drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key companies in the Prurigo Nodularis market include:
Menlo Therapeutics
Trevi Therapeutics
Kiniksa Pharmaceuticals
Galderma
Sanofi
And others.
Prurigo Nodularis Therapies Covered in the Report includes Serlopitant, Nalbuphine ER, KPL-716, Nemolizumab, Dupilumab, and many others.
Source: Prurigo Nodularis Market Growth